Eradivir, a preclinical biotech company, has developed a patent-pending antiviral therapeutic that reduces lung viral loads of advanced-stage influenza in preclinical studies quicker and more effectively than currently available therapies. A single intranasal dose of EV25, a bispecific small molecule developed by Eradivir, acts faster than the current standard of care, eliminating the detectable virus within 24 hours. EV25 also has a window of efficacy of 96 hours postinfection, which is broader than the current standard of care.
A research paper titled "Targeted recruitment of immune effector cells for rapid eradication of influenza virus infections" has been published in Proceedings of the National Academy of Sciences. EV25 was built on a platform created by Philip Low, the Presidential Scholar for Drug Discovery and the Ralph C. Corley Distinguished Professor of Chemistry in Purdue University's College of Science.
He is part of Purdue's One Health initiative and on the faculty of the Purdue Institute for Drug Discovery and the Purdue Institute for Cancer Research. Low is Eradivir's chief scientific officer and on its board of directors. He disclosed the immunological innovations to the Purdue Innovates Office of Technology Commercialization, which has applied for patents to protect the intellectual property.
OTC licensed the innovations to Eradivir for further development and commercialization. Serious threats posed by influenza Imrul Shahriar, a scientist at Eradivir, sai.
